Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | HRH2 | P25021 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120195 | 0.82 | USP2 (0.49) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| SCHEMBL1619064 | 0.82 | HRH3 (0.70) | HRH3HRH1HRH2KCNH2 | |
| SCHEMBL2969469 | 0.81 | KCNH2 (0.43) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| SCHEMBL2961531 | 0.81 | HRH2 (0.45) | HRH3HRH1HRH2KCNH2KDM1A | |
| SCHEMBL4505273 | 0.81 | HRH1 (0.37) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| Hydrochloric Acid SCHEMBL1619344 | 0.81 | USP2 (0.48) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| Hydrochloric Acid SCHEMBL1619076 | 0.81 | HRH3 (0.68) | HRH3HRH1HRH2KCNH2 | |
| Hydrochloric Acid SCHEMBL4521680 | 0.81 | KCNH2 (0.36) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| SCHEMBL2962586 | 0.81 | HTR1A (0.47) | HRH3HRH1HRH2KCNH2KCNJ1 | |
| SCHEMBL2967590 | 0.80 | KCNH2 (0.44) | HRH1HRH2KCNH2KCNJ1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1389212-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | disclosed |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | US | disclosed |
| EP-1389211-A1 | 3,7-DIAZYBICYCLO 3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1389212-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | HRH3 936/4885HRH1 765/4885HRH2 680/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | HRH3 817/4885HRH1 970/4885HRH2 1257/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 385/4885HRH1 526/4885HRH2 505/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 420/4885HRH1 591/4885HRH2 556/4885 |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | HCN3, CACNB3, TNNI3 | HRH3 3165/4885HRH1 3815/4885HRH2 3157/4885 |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | HRH3 2620/4885HRH1 3026/4885HRH2 3252/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 385/4885HRH1 526/4885HRH2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.